“…9 Pyrazole-pyrimidine derivatives bearing 1,2,4-oxadiazole were tested in vitro for anti-tumor activity in a panel of 12 human tumor cell lines, finding that N 3 -(4-(3-(tertbutyl)-1,2,4-oxadiazol-5-yl)phenyl)-6-phenyl-1H-pyrazolo[3,4d]pyrimidine-3,4-diamine has a moderate overall potency, combined with good selectivity towards the renal cancer cell line RXF 393. 10 4-Chloro-benzamides derivatives containing the 1,2,4-oxadiazole core, afforded a new class of receptor tyrosine kinase inhibitors, showing comparable activity to the multitargeted tyrosine-kinase inhibitor Ponatinib. 11 Considering that the 1,2,4-oxadiazolic ring is an important part of many biologically active compounds and the potential antitumor activity of the diheterocyclic 2,3-O-cyclopentylideneβ-D-ribofuranoside compounds, we envisioned the preparation of a small and focused library of compounds bearing both structural features.…”